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Abstract: Background: Mangosteen and propolis extracts (MAEC) have been potential therapeutic
agents known to exhibit powerful antioxidant and anti-inflammatory properties. The aim of the
current study was to evaluate the clinical and immunological efficacy of MAEC as well as safety and
patient-reported outcomes (PROMs) on gingivitis and incipient periodontitis. Methods: This study
was performed on 104 patients diagnosed with gingivitis or incipient periodontitis. At baseline, the
participants were randomly allocated to either the test group, with daily intake of a single capsule
containing 194 mg of MAEC for eight weeks, or control group, with placebo. Clinical periodontal
evaluation and immunological parameters from saliva and gingival sulcular fluid were assessed
at baseline, four, and eight weeks. Individual PROMs were assessed by OHIP-14 questionnaires.
Results: There was a significant difference of modified gingival index at four and eight weeks
between the test and control groups. In the test group, crevicular interleukin (IL)-6 was reduced,
and the salivary matrix metalloproteinase (MMP)-9 was increased after eight weeks. PROMs were
improved up to four weeks compared to placebo. Conclusion: Oral administration of MAEC would
have a potential to reduce gingival inflammation clinically and immunologically in the patients with
gingivitis and incipient periodontitis.
Keywords: mangosteen; propolis; gingivitis
1. Introduction
Gingivitis is an inflammatory condition initiated by the accumulation of dental biofilm
and is characterized by gingival swelling and redness [1]. Periodontitis is the more progres-
sive form of inflammation that results in the loss of periodontal attachment and is caused by
a multitude of factors, including oral bacteria and host immunity [2]. Often, periodontitis
can progress unnoticed, but the eventual loss of teeth is irreversible. Achieving good oral
hygiene has been and still is the key to prevention and treatment of these inflammatory
disorders [3–5]. The standard of care for periodontitis in the professional setting includes
mechanical debridement to remove the pathologic biofilm along with the application of
antimicrobials. In recent times, research has shown that it is the host’s immunity that is
responsible for the progression of inflammation and destruction of periodontium [6]. There-
fore, immune-modulation therapies, such as oral bisphosphonates or tetracyclines, have
been introduced to achieve the blockage of proinflammatory pathways related to secretion
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of immune-regulatory cells in the periodontitis niche [7,8], but side-effects or short-comings
have been common [6]. Nowadays, the focus on compounds derived from medicinal plants
and natural products have increased [9,10]. Safe and efficacious substances extracted from
natural sources known to contain antioxidant and anti-inflammatory properties can be
taken as daily supplements to reduce the unknown risk of periodontitis.
Mangosteen (Garcinia mangostana L.) is an exotic, tropical fruit known for its use
in traditional medicine to treat diarrhea, infected wounds, suppuration, and chronic ul-
cers [10]. The pericarp of mangosteen is a rich source of xanthones, including α-mangostin,
β-mangostin, and γ-mangostin. Xanthones have been shown to exhibit various phar-
macological properties, including antioxidant, antimicrobial, anti-carcinogenic, and anti-
allergic [11]. In particular, α-mangostin compounds exhibit anti-inflammatory activity by
inhibiting the production of nitrous oxide, TNF-α, and interleukin-8. A randomized clinical
trial using local delivery of 4% mangostana gel into the periodontal pockets of chronic
periodontitis patients showed significant improvement in periodontal parameters [12].
Propolis is a viscous substance produced by bees that exhibits antimicrobial, anti-
inflammatory, and antioxidant properties [13,14]. Propolis is well-documented in the
scientific literature and is known to be non-toxic [15]. Propolis comprises over 200 in-
gredients, including flavonoids, cinnamic acids, caffeic acids, and caffeic acid phenethyl
ester [16]. A meta-analysis on the effectiveness of propolis treatment for periodontitis has
shown that it reduced probing pocket depth as compared with placebo [15]. Propolis has
been locally delivered in various forms, such as mouthwash, toothpaste, irrigation, and
subgingival gel [15], and has been reported to reduce plaque formation and exhibit an-
timicrobial effects against some key periodontal pathogens [17–19]. Furthermore, propolis
has been studied extensively for its anti-oxidative property [14], which could be beneficial
for treatment of periodontitis, as reduction in oxidative stress may decrease secretion of
pro-inflammatory cytokines and prevent alveolar bone loss. One study used propolis as a
dietary supplement accompanied by scaling in patients with chronic periodontitis and type
2 diabetes mellitus [20]. Not only was it effective for lowering diabetic biomarkers, such as
HbA1c (glycosylated hemoglobin), but also it significantly reduced periodontal parameters.
A recent in vitro study described that the combination of 1:34 ratio in weight of
mangosteen and propolis extract were highly effective for reducing IL-6, IL-8, and PGE2
expression in immortalized human fibroblasts treated with lipopolysaccharides (LPS) of
Porphyromonas gingivalis. Additionally, it was able to induce the most bone forming activity
from human osteoblast-like cells. However, there are no clinical studies up to date to
verify the efficacy and safety of MAEC [21]. Therefore, the aim of the present randomized
controlled trial was to confirm the clinical and immunological outcomes of systemically
taken MAEC as well as patient-reported outcomes (PROMs) on patients with gingivitis
and incipient periodontitis.
2. Materials and Methods
2.1. Study Design and Participants
This study was designed as a multi-centered, double-blinded, parallel-armed, placebo-
controlled randomized clinical trial. The study was registered with the Clinical Research
Information Service of the National Research Institute of Health in the Republic of Ko-
rea (KCT0005569). Clinical measurements between investigators were standardized via
calibration meetings prior to trial commencement. All procedures were adhering to the
Declaration of Helsinki and good clinical practice guidelines and approved by the Institu-
tional Review Board of the Yonsei University Dental Hospital (2-2019-0025), Kyung Hee
University Dental Hospital (KH-DT19014), and Veterans Health Service Medical Center
(2019-05-018). A total of 104 subjects were enrolled from the Department of Periodontology,
Yonsei University Dental Hospital; Department of Periodontology, Kyung Hee University
Dental Hospital; and Veterans Health Service Medical Center from September 2019 to
March 2020. Before enrollment, all participants were informed about the nature of the
study, and informed consent form was obtained. The CONSORT flowchart is presented
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in Figure 1. The clinical data collection was performed by the resident dentists at the
periodontics department of each center.
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2.2. Inclusion and Exclusion Criteria
This study was performed on patients diagnosed as generalized or localized gingivi-
tis or stage I periodontitis according to the 2017 World Workshop Consensus Report [2].
Further inclusion criteria were (1) being >20 and <75 years of age and in good general
health, (2) having a minimum of 18 teeth, (3) having BOP (bleeding on probing) sites of
>10%, and (4) having at least one tooth with PD (probing depth) of >3 mm and ≤5 mm.
The exclusion criteria were (1) not providing written informed consent; (2) having received
preventive periodontal therapy within 3 months prior to screening; (3) having a serious
oral mucosal disease such as oral cancer; (4) having >5 carious teeth that require treatment;
(5) being diagnosed as chronic moderate or advanced periodontitis; (6) smoking; (7) taken
antibiotics in the 3 months prior to screening; (8) having uncontrolled diabetes (fasting
blood glucose level > 180 mg/dL); (9) having elevated AST(GOT) or ALT(GPT) levels > 3 times
the ULN(upper limit of normal); (10) having creatinine level > twice the ULN; (11) having
bleeding disorders or history of hemorrhage and receiving preventive antiplatelet or anti-
coagulant medication; (12) having a significant cardiovascular, immunological, infectious,
or oncological illness, (13); having a mental illness, such as schizophrenia, depression, and
drug/alcohol addiction; (14) being allergic to the test substance; (15) being pregnant or
lactating; (16) participating in other clinical trials; and (17) judged as being unsuitable for
study inclusion by the clinician for some other reason.
2.3. Baseline Evaluation
At baseline, clinical examination along with physical examination, measurement of
salivary and sulcus biomarkers, and OHIP-14 (oral health impact profile) questionnaire
were completed. The OHIP-14 questionnaire was a Korean version that had been vali-
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dated [22]. Suitability for study inclusion was assessed according to results of examinations
from screening and baseline. The included participants were instructed not to receive other
therapeutic agents or therapy during the study, including medication or treatment aid for
periodontal disease, antiplatelets or anticoagulants, antioxidant vitamins, antibiotics for
>1 week, anti-inflammatory drugs, orthodontic treatment or scaling, and mouthwash.
2.4. Intervention and Monitoring
At baseline, the participants were randomly allocated to the following groups:
• Test group: Daily intake of a single capsule containing 194 mg of MAEC for 8 weeks
(56 days).
• Control group: Placebo capsule without MAEC given in equal administration as the
test group.
The dosage and composition of MAEC was determined based on a previous preclinical
study. In brief, α-mangostin was extracted from the pericarp of mangosteen fruit and total
flavonoids from propolis. The extracted substances were combined at the ratio of 1:34 by
weight (mangosteen:propolis). The effective dose in rodents in the previous study was
2.8 mg/kg by weight [23,24]. When converted for an adult human of 70 kg, the dose was
approximately 194 mg. The details of the constituents of the test and placebo capsules are
shown in Table 1.
Table 1. The details of the constituents of the test and placebo capsules.
Placebo Test
Raw Material CompoundingRatio (%) Content (mg)
Compounding
Ratio (%) Content (mg)
Mangosteen and propolis extracted complex - - 41.28 194.00
Lactose powder 62.70 294.69 30.00 141.00
Microcrystalline cellulose 34.27 161.07 24.22 113.85
Sucrose esters of fatty acids - - 2.00 9.40
Magnesium stearate 1.00 4.70 1.50 7.05
silicon dioxide - - 1.00 4.70
Caramel color 2.00 9.40 - -
Food blue No.1 0.03 0.14 - -
Total 100 470 100 470
No professional oral prophylaxis was provided at the beginning or during the study
period, and the participants were instructed to continue with their daily oral hygiene.
Scaling was provided at the completion of the study, at week 8. Dietary analysis was
performed on each visit, and patients were instructed to avoid regular consumption of
foods containing mangosteen and propolis. Nutritional analysis of the obtained data was
carried out using an online software (Can 5.0, The Korean Nutrition Society, Seoul, Korea).
For immunological analysis, one tooth from each participant displaying the deepest probing
depth was chosen and gingival cord was placed in the gingival sulcus for 1 min to collect
gingival crevicular fluid (GCF). Saliva was collected by drooling of unstimulated whole
saliva. Samples were analyzed using RNA expression and enzyme-linked immunosorbent
assay (ELISA). OHIP-14 questionnaire was completed at baseline, 4, and 8 weeks. Safety
was monitored by: (i) reporting of any adverse event or drug reaction throughout the study
period; (ii) physical examination and vitality tests (blood pressure and pulse) performed at
screening, 4, and 8 weeks; and (iii) pathological tests on urine and blood samples performed
at screening and 8 weeks. In the reporting of adverse drug reaction, the severity of adverse
event was recorded according to the grading system recommended by the World Health
Organization [25].
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2.5. Randomization and Blinding
The participants were randomly allocated to one of two study groups, with fifty
patients in each group. Randomization sequence was generated by SAS® system’s (version
9.4, SAS Institute, Cary, NC, USA) randomization program. Sealed envelopes containing
manufactured capsules were labeled with unique identification codes that were sent to the
clinical centers and sequentially allocated to the enrolled participants on baseline. Identity
of the double-blinded samples remained undisclosed until the end of the trial unless the
participant was to be excluded.
2.6. Clinical Parameters and Immunological Biomarkers for Evaluation of Efficacy
All clinical parameters were recorded on every visit of active treatment. The efficacy
of MAEC was evaluated by comparing periodontal indices and immunological indicators
at each stage of the trial. The primary outcome of the study was the change in modified
gingival index (GI) [26]. Modified GI was recorded at two surfaces of each tooth (buccal
and lingual) and every tooth of each patient. The secondary outcomes were changes in PD
(probing depth), CAL (clinical attachment loss), PI (plaque index) [27], BOP (bleeding on
probing), GR (gingival recession), salivary and crevicular fluid biomarkers (interleukin-1 β
(IL-1β), interleukin-6 (IL-6), matrix metalloproteinase-8 (MMP-8), matrix metalloproteinase-
9 (MMP-9)), and OHIP-14 (Oral Health Index Profile-14) [28].
2.7. Sample Size Estimation
The two-sided test was used to determine the sample size. A previous study having
the same evaluation variable as the current study was referred to for calculation [29]. A
minimum sample size of 40 patients in each group was needed to detect a clinically relevant
difference in the primary outcome measurement between the test and control groups with
a statistical power of 80% and a significant level of 5% (SD = 0.5). Considering an estimated
dropout rate of 20%, the required sample size was determined to be 100 patients in total.
2.8. Statistical Analysis
Statistical analysis was performed with commercially available software SAS® (Version
9.4, SAS Institute). Changes in clinical parameters within the groups between time points
were analyzed using either the Paired t-test or Wilcoxon signed-rank test according to
result of the normality test. Inter-group analysis at each time point was made using the
two-sample t-test or Wilcoxon rank-sum test. The Mann–Whitney U test and chi-square
tests were used to compare demographic characteristics and clinical index between the test
and control groups. Smoking, age, sex, alcohol consumption, and obesity were considered
as covariates for generalized linear model in efficacy evaluation, as these factors are known
to be closely related to the dependent variables. The data were presented in mean and
standard deviation, and statistical significance of difference between two groups was
defined as p < 0.05.
2.9. Data Set Characterization
The data collected from the current study were categorized into safety set, FA (full
analysis) set, and PP (per protocol) set. The safety set included any participant that ingested
the test product at least once. According to the ITT (intention to treat) protocol, FA set
included any participant that received the test product at least once, attended at 4 and
8 weeks for efficacy evaluation, and adhered to the inclusion/exclusion criteria. PP set
included only the participants that completed the study with adherence to the inclusion
criteria. The PP set was used mainly for the evaluation of efficacy, and the FA set analysis
was performed additionally. The safety set was used for the safety analysis.
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3. Results
3.1. Participant Flow and Baseline Data
Total 104 patients were enrolled for randomization (52 test, 52 control). Five par-
ticipants failed to attend after baseline evaluation, and two did not adhere to the inclu-
sion/exclusion criteria. Therefore, 97 participants were included in the FA set. From
the FA set, 10 subjects attended outside of the visit window, 3 had taken contraindicated
medications, and 4 failed to sign required consent forms. Therefore, 80 subjects completed
the study and were included in the PP set (n = 41 and 39 for test and control groups,
respectively) (Figure 1). Among the baseline characteristics, no statistically significant
difference between the test and control groups was found. The baseline demographics and
clinical characteristics of each group were presented in Table 2.
Table 2. Demographics and clinical characteristics of participants.
Variables Control Group(n = 39)
Test Group
(n = 41) p-Value
Age (years), mean ± SD 33.41 ± 6.89 35.95 ± 10.64 0.4520 †
Gender, n (%)
Male 7 (17.95) 12 (29.27)
0.2344 #Female 32 (82.05) 29 (70.73)
Smoking status, n (%)
No 39 (100.00) 41 (100.00) -
Yes 0 (0.00) 0 (0.00)
Physical activity, n (%)
None 11 (28.21) 13 (31.71)
0.1057 ‡
1–2 times/week 10 (25.64) 8 (19.51)
3 times/week 15 (38.46) 8 (19.51)
4–5 times/week 2 (5.13) 7 (17.07)
7 times/week 1 (2.56) 5 (12.20)
Drinking status, n (%)
None 24 (61.54) 17 (41.46)
0.3504 ‡
Quit drinker 0 (0.00) 1 (2.44)
Light drinker 7 (17.95) 13 (31.71)
Moderate drinker 6 (15.38) 7 (17.07)
Heavy drinker 2 (5.13) 3 (7.32)
Dental treatment within 3 months, n (%)
No 38 (97.44) 41 (100.00)
0.4875 ‡Yes 1 (2.56) 0 (0.00)
Height (cm), mean ± SD 165.58 ± 6.44 164.43 ± 9.55 0.2052 #
Number of natural teeth, mean ± SD 26.69 ± 1.94 27.56 ± 1.82 0.0654 #
# Obtained from Wilcoxon rank-sum test, † obtained from chi-square test, ‡ obtained from Fisher’s exact test.
3.2. Outcomes
3.2.1. Clinical Parameters
The results on clinical parameters for primary and secondary outcomes are summa-
rized in Table 3. Modified GI showed statistically significant reduction in both test and
control groups after four (p = 0.0002 and 0.004, respectively) and eight weeks (p < 0.0001,
p = 0.004, respectively). The amount of reduction was greater in the test group than control
group at both four (p = 0.018) and eight weeks (p = 0.041). PD, CAL, PI, BOP, and GR showed
significant reduction in the test group after eight weeks. However, inter-group analysis
showed no significant difference in these parameters between test and control groups.
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Table 3. Clinical parameters of test and control group (mean ± SD).
Parameters Study Group Baseline † 4 Weeks ‡ 8 Weeks ‡
PD
Control 2.46 ± 0.25 2.42 ± 0.26 2.42 ± 0.24
Test 2.58 ± 0.27 2.57 ± 0.27 2.46 ± 0.34
p-value
(Test vs. Control) 0.0618 0.1761 0.7879
CAL
Control 2.57 ± 0.26 2.53 ± 0.24 2.48 ± 0.25
Test 2.67 ± 0.27 2.64 ± 0.29 2.54 ± 0.28
p-value
(Test vs. Control) 0.0743 0.5005 0.5940
BOP
Control 41.12 ± 11.20 34.44 ± 16.83 27.00 ± 13.90
Test 42.56 ± 12.76 31.31 ± 16.95 27.65 ± 19.22
p-value
(Test vs. Control) 0.6371 0.1231 0.7272
GR
Control 0.38 ± 0.19 0.28 ± 0.21 0.24 ± 0.19
Test 0.31 ± 0.15 0.22 ± 0.21 0.23 ± 0.19
p-value
(Test vs. Control) 0.1891 0.9078 0.5763
MGI
Control 0.79 ± 0.22 0.66 ± 0.46 0.59 ± 0.53
Test 0.84 ± 0.33 0.58 ± 0.46 0.50 ± 0.51
p-value
(Test vs. Control) 0.8884 0.0184 * 0.0406 *
PI
Control 0.91 ± 0.31 0.78 ± 0.49 0.78 ± 0.40
Test 0.93 ± 0.33 0.78 ± 0.48 0.66 ± 0.46
p-value
(Test vs. Control) 0.9374 0.9143 0.1354
* Statistically significant correlation at p < 0.05. † Obtained from Wilcoxon rank-sum test. ‡ Obtained from
generalized linear model adjusted baseline, smoke, age, sex, drink, obesity. PD, probing depth; CAL, clinical
attachment loss; BOP, bleeding on probing; GR, gingival recession; MGI, modified gingival index; PI; plaque index.
3.2.2. Immunological Parameters
The results on immunological parameters are illustrated in Figure 2. Crevicular
IL-6 showed significant reduction in the test group between baseline and eight weeks
(p = 0.006). However, no inter-group difference was noted in any of the crevicular fluid
markers. Salivary MMP-8 was significantly reduced in control group (p = 0.022) after eight
weeks. Salivary MMP-9 showed significant increase in test group (p = 0.041). Inter-group
analysis showed significant difference in salivary MMP-9 between the groups (p = 0.043).
However, when adjusted for covariates (smoke, age, sex, drink, obesity) in the generalized
linear model, no statistical significance was found. FA set analysis showed no significant
difference in inter-group analysis of all salivary markers.





Figure 2. Biomarkers in salivary sample and gingival crevicular fluid. * Significant difference between test and control (p 
< 0.05). GCF: gingival crevicular fluid, IL-1β: Interleukin-1 β, IL-6: interleukin-6, MMP-9: matrix metalloproteinase-9, 
MMP-8: matrix metalloproteinase-9.  
3.2.3. Safety Analysis 
The safety set data were used to perform the safety analysis (104 in total, 52 in each 
group). In the test group, eight patients reported nine incidents of mild adverse events, 
whereas in the control group, eight patients reported ten mild incidents. There was no 
statistically significant difference between the two groups, and there were no drop-outs 
among the reported patients. The most frequently reported adverse event was infection 
or parasitic infection for both test and control groups (5.77% and 7.69%, respectively). 
Figure 2. Biomarkers in salivary sample and gingival crevicular fluid. * Significant difference between test and control
(p < 0.05). GCF: gingival crevicular fluid, IL-1β: Interleukin-1 β, IL-6: interleukin-6, MMP-9: matrix metalloproteinase-9,
MMP-8: matrix metalloproteinase-9.
3.2.3. Safety Analysis
The safety set data were used to perform the safety analysis (104 in total, 52 in each
group). In the test group, eight patients reported nine incidents of mild adverse events,
whereas in the control group, eight patients reported ten mild incidents. There was no
statistically significant difference between the two groups, and there were no drop-outs
among the reported patients. The most frequently reported adverse event was infection or
parasitic infection for both test and control groups (5.77% and 7.69%, respectively). Acute
gastroenteritis was the most relevant adverse drug reaction among the reported incidents,
and it occurred in one patient from the control group. The patient healed spontaneously
and completed the study. The clinical parameters for various tests are shown in Table 4.
Blood tests revealed that RBC (red blood cell), Hb (hemoglobin), and Hct (hematocrit)
were increased in the test group after eight weeks and decreased in control group. These
changes were within the limits of normality. Inter-group analysis also showed statistical
significance for each of these categories.




(n = 52) p-Value
n Mean ± SD n Mean ± SD
WBC
(103/µL)
Baseline 52 6.37 ± 1.50 52 5.91 ± 1.48 0.0885 #
8 weeks 50 6.16 ± 1.42 48 6.03 ± 1.65 0.1850 #
p-value 0.2574 ** 0.3750 @
RBC
(106/µL)
Baseline 52 4.48 ± 0.39 52 4.55 ± 0.43 0.7158 #
8 weeks 50 4.48 ± 0.38 48 4.61 ± 0.40 0.0483 *
p-value ** 0.8040 0.0101





(n = 52) p-Value
n Mean ± SD n Mean ± SD
Hb
(g/dL)
Baseline 52 13.50 ± 1.05 52 13.94 ± 1.22 0.1361 #
8 weeks 50 13.54 ± 1.06 48 14.18 ± 1.18 0.0381 *
p value ** 0.8624 0.0020
Hct
(%)
Control 52 40.27 ± 3.04 52 41.06 ± 3.28 0.3907 #
Test 50 40.30 ± 3.07 48 41.83 ± 3.39 0.0120 *
p-value ** 0.8583 0.0003
PLT
(103/µL)
Baseline 52 255.69 ± 54.75 52 269.40 ± 54.23 0.1340 #
8 weeks 50 253.74 ± 52.71 48 268.27 ± 54.60 0.8496 *
p-value ** 0.4001 0.3227
AST(GOT)
(IU/L)
Baseline 52 19.38 ± 7.95 52 21.00 ± 8.81 0.0356 #
8 weeks 50 20.18 ± 10.53 48 21.06 ± 8.38 0.9517 #
p-value 0.9147 @ 0.7794 **
ALT(GPT)
(IU/L) @
Baseline 52 16.23 ± 9.02 52 19.81 ± 16.81 0.1501 #




Baseline 52 94.69 ± 12.52 52 97.56 ± 17.03 0.5195 #




Baseline 52 12.27 ± 3.15 52 12.78 ± 3.58 0.6419 #
8 weeks 50 11.88 ± 2.77 48 12.44 ± 3.42 0.8643 *
p-value ** 0.3753 0.5011
Creatinine
(mg/dL)
Baseline 52 0.74 ± 0.13 52 0.77 ± 0.16 0.5715 #
8 weeks 50 0.73 ± 0.14 48 0.76 ± 0.15 0.8625 *
p-value ** 0.5020 0.6074
Boldface denotes statistical significance (p < 0.05). * Compared between groups; p-value for Two sample t-test, # compared between
groups; p-value for Wilcoxon rank-sum test, ** compared within group; p-value for paired t-test, @ compared within group; p-value for
Wilcoxon signed-rank test. WBC, white blood cell; RBC, red blood cell; Hb, hemoglobin; Hct, hematocrit; PLT, platelet; AST, aspartate
aminotransferase; ALT, alanine transaminase; BUN, blood urea nitrogen.
3.2.4. Patient-Reported Outcome Measurements (PROMs)
Higher scores from the OHIP-14 questionnaire reflect worse outcome reported by the
patients. The results from OHIP-14 were presented on Table 5. The scores from questions
regarding functional limitation at four weeks were significantly increased among control
group compared to baseline (p = 0.034). There was a significant difference between test
and control groups at four weeks (p = 0.049), which was also evident in the analysis of
the FA set. The scores from questions on taste disturbance at four weeks were lower for
the test group compared to the control (p = 0.01) in the FA set analysis. In response to
the question “Have you felt your diet has been unsatisfactory?”, the test group scored
significantly lower at both time points compared to baseline (p = 0.03 and 0.01 at four and
eight weeks, respectively). These scores were significantly lower than for placebo (p = 0.02
and 0.03 at four and eight weeks, respectively).
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n = 48 p-Value
# p-Value $





Baseline 1.33 ± 0.63 1.27 ± 0.49 0.8237
4 weeks 1.43 ± 0.65 1.23 ± 0.63 0.2088 0.2100
p-value @ 0.2830 0.7813
8 weeks 1.24 ± 0.43 1.19 ± 0.49 0.5968 0.7856
p-value @ 0.6334 0.3984
Worsened sense of
taste
Baseline 1.16 ± 0.43 1.17 ± 0.43 0.9717
4 weeks 1.22 ± 0.42 1.06 ± 0.24 0.0212 0.0173
p-value @ 0.3750 0.1250
8 weeks 1.22 ± 0.42 1.10 ± 0.31 0.1371 0.1229
p-value @ 0.5488 0.3750
Physical pain
Painful aching
Baseline 1.45 ± 0.74 1.50 ± 0.68 0.5463
4 weeks 1.45 ± 0.68 1.33 ± 0.63 0.1709 0.3582
p-value @ 1.0000 0.1668
8 weeks 1.39 ± 0.67 1.31 ± 0.59 0.2082 0.5073
p-value @ 0.6334 0.0930
Uncomfortable to
eat
Baseline 1.53 ± 0.79 1.54 ± 0.71 0.7229
4 weeks 1.55 ± 0.77 1.38 ± 0.64 0.0880 0.1439
p-value @ 0.9744 0.1710
8 weeks 1.35 ± 0.56 1.25 ± 0.53 0.4344 0.6614




Baseline 1.65 ± 1.01 1.58 ± 0.82 1.0000
4 weeks 1.53 ± 0.77 1.35 ± 0.73 0.3905 0.4626
p-value @ 0.2970 0.0986
8 weeks 1.35 ± 0.63 1.35 ± 0.70 0.5869 0.4328
p-value @ 0.0178 0.1108
Felt nervous
Baseline 1.80 ± 0.91 1.83 ± 0.97 0.9126
4 weeks 1.80 ± 0.91 1.60 ± 0.84 0.1712 0.2543
p-value @ 0.9073 0.0467
8 weeks 1.69 ± 0.87 1.42 ± 0.71 0.2012 0.0997




Baseline 1.43 ± 0.68 1.56 ± 0.68 0.2451
4 weeks 1.47 ± 0.62 1.33 ± 0.60 0.0214 0.1167
p-value @ 0.7539 0.0340
8 weeks 1.49 ± 0.71 1.29 ± 0.50 0.0377 0.1518
p-value@ 0.5797 0.0124
Interrupted meals
Baseline 1.47 ± 0.84 1.44 ± 0.71 0.9717
4 weeks 1.33 ± 0.52 1.31 ± 0.62 0.7604 0.9048
p-value @ 0.1975 0.3150
8 weeks 1.29 ± 0.54 1.25 ± 0.56 0.7977 0.8772
p-value @ 0.1715 0.0571
Psychological
disability Difficult to relax
Baseline 1.78 ± 0.87 1.88 ± 0.96 0.6722
4 weeks 1.84 ± 0.96 1.58 ± 0.92 0.0813 0.0629
p-value @ 0.7842 0.0032
8 weeks 1.61 ± 0.79 1.48 ± 0.71 0.1015 0.2839
p-value @ 0.1865 0.0046





n = 48 p-Value
# p-Value $
Mean ± SD Mean ± SD
Embarrassment
Baseline 1.61 ± 0.81 1.50 ± 0.68 0.5996
4 weeks 1.55 ± 0.84 1.29 ± 0.50 0.5498 0.2202
p-value @ 0.7129 0.0458 0.6297 0.5198
8 weeks 1.31 ± 0.55 1.17 ± 0.38





Baseline 1.82 ± 0.88 1.81 ± 0.89 0.9690
4 weeks 1.94 ± 1.09 1.77 ± 0.88 0.3775 0.4092
p-value @ 0.4119 0.8257
8 weeks 1.65 ± 0.88 1.52 ± 0.74 0.5813 0.6269
p-value @ 0.2173 0.0239
Difficulty doing
usual jobs
Baseline 1.47 ± 0.71 1.44 ± 0.68 0.8563
4 weeks 1.61 ± 0.81 1.40 ± 0.68 0.2417 0.3442
p-value @ 0.2523 0.8074
8 weeks 1.37 ± 0.64 1.21 ± 0.50 0.2329 0.2243
p-value @ 0.3635 0.0510
Handicap
Less satisfaction
Baseline 1.55 ± 0.77 1.50 ± 0.74 0.6916
4 weeks 1.67 ± 0.88 1.52 ± 0.71 0.6577 0.7531
p-value @ 0.1855 0.9542
8 weeks 1.35 ± 0.66 1.35 ± 0.56 0.7046 0.4157
p-value @ 0.0861 0.1185
Unable to function
Baseline 1.22 ± 0.42 1.10 ± 0.31 0.1135
4 weeks 1.18 ± 0.49 1.13 ± 0.33 0.4418 0.8228
p-value @ 0.7539 1.0000
8 weeks 1.12 ± 0.33 1.13 ± 0.33 0.1312 0.3290
p-value @ 0.2266 1.0000
#: Compared between groups; p-value for Wilcoxon rank-sum test; $ Compared between groups; p-value for GLM-adjusted baseline, smoke,
age, sex, drink, obesity; @ Compared within group; p-value for Wilcoxon signed-rank test.
4. Discussion
In the present clinical trial, MAEC capsules were orally administered for up to two
months in patients with gingivitis and incipient periodontitis and were compared with
placebo. The main findings were (i) daily ingestion of MAEC resulted in significant
reduction of modified GI at four and eight weeks compared with placebo; (ii) a daily intake
of the current dose (194 mg) was safe and without any considerable adverse events; and
(iii) MAEC intake significantly improved PROMs compared to placebo.
Modified GI of the test group in the present study decreased significantly at both
four-week and eight-week time points and compared to the control group. This was
accompanied by reduction in other clinical parameters, including PD, BOP, CAL, and GR
after eight weeks, although significant difference to the control group was not demonstrated
for these variables. Modified GI is a non-invasive modification of the GI [27] and has been
generally accepted for use in clinical trials. Evidence indicates that non-invasive indices,
such as the modified GI, are capable of providing comparable data to invasive indices like
BOP [30]. Since modified GI expands the low end of the scale of GI to increase sensitivity
for assessing gingival inflammation, it was appropriate for detecting subtle changes in the
gingival status of patients with mild inflammation, such as in this study.
The present study investigated the effect of MAEC per se without scaling and root
planning at baseline. Scaling and root planing disrupts and reduces the gingival and
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subgingival microbiota [31], which would cause improvement in the clinical parameters.
By utilizing the current study design, the focus can be drawn to the influence of MAEC on
the host’s response to a chronic bacterial insult. A chronic lesion is one that is characterized
by unresolved inflammation, resulting in the loss of tissue structure and function [32].
However, it is still possible that some of the sites of inflammation might be periodic lesions
that spontaneously heal with the body’s natural immune system. This was evident in the
reduction of modified GI in the placebo group up to eight weeks compared to baseline.
Yet, the significant difference in the reduction of modified GI between the test and control
groups shows that MAEC would be acting as the catalyst in speeding up the resolution
of inflammation.
The results from the immunological parameters in this study were somewhat indica-
tive of the reduction of inflammation. The crevicular IL-6 levels decreased after eight weeks
but not significantly compared to the placebo. It was reported that IL-6 was produced
by T cells, macrophages, and osteoblasts and was a regulator of T- and B-cell growth and
stimulates osteoclast formation [33]. Along with IL-1β, IL-6 in the GCF has been associated
with deep PDs and severe gingival inflammation in a sample size of over 6000 patients [34].
The persistent secretion of proinflammatory cytokines, including tumor necrosis factor al-
pha (TNF-α), IL-1β, IL-6, and IL-12, combined with reduced levels of regulatory cytokines,
including IL-10, and transforming growth factor beta 1 (TGF-β1), has been linked with
sustained inflammation and loss of periodontal attachment [35]. Therefore, the reduction
of IL-6 in the GCF is in correlation with the improvement of the clinical parameters in
this study.
The MMP-9 levels in the saliva were significantly increased in the MAEC group after
eight weeks, and this increase was greater than the placebo group. However, when the
results were adjusted for covariates, no difference was found. MMP-8 and MMP-9 were
chosen for assessment in this study as they are the most common MMPs in periodontal
tissues that indicate periodontitis progression, severity, and treatment response [36]. MMPs
have been related to a wide spectrum of inflammatory diseases and were traditionally
regarded as collagenases and gelatinases that degrade extracellular matrix components [37].
However, further research into MMPs has brought the appreciation of the vast complexity
of MMP functions that places them into the present idea of the “protease web” [38]. MMPs
have been suggested as the main regulators of inflammation as well as multifunctional
proteins, causing pro- or anti-inflammatory reactions that lead to either pathology or
homeostasis. In an in vitro study using human fibroblasts, MMP activity reduced the
secretion of IL-6 while increasing the secreted levels of some proinflammatory chemokines
that activates leukocytes [39], which concurs with the immunological parameters in this
study. On the other hand, a meta-analysis involving an excess of 6000 subjects suggested
that MMP-9 reduced the risk of periodontitis, whereas MMP-3 and -8 increased the risk of
periodontitis [40]. Given that there was a significant reduction of gingival inflammation in
the MAEC group with increase in the MMP-9, the current evidence may support the result
of that meta-analysis.
The MAEC in this study has been studied previously to determine its anti-inflammatory
effect. In addition, the anti-inflammatory effect of MAEC was greater than when mangos-
teen and propolis extracts were used alone and in combinations with varying concentra-
tions, which suggests that there might be a synergistic effect between the two substances in
that specific combination [21]. Since the present study was performed using oral adminis-
tration, it is unknown whether the same concentration of the mixture was present in the
target tissues of the subjects. Although there is abundance of preclinical studies on antioxi-
dant anti-inflammatory properties of mangosteen and propolis, pharmacokinetics of the
two substances have received limited attention. A previous study in rodents has revealed
that intravenously injected α-mangostin was rapidly distributed and slowly eliminated
from blood; however, when orally administered, the bioavailability was low [41]. A more
recent study in rodents showed that delivery of xanthones in the form of mangosteen fruit
extracts exhibited greater bioavailability of free α-mangostin in serum compared to the
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delivery in the form of pure xanthones due to slower rate of conjugation [42]. In a human
study using oral administration of xanthone-rich fruit juice, xanthones were found to be
absorbed and partially conjugated in healthy adults, but there was a high variability in the
concentrations found in the plasma and urine [43]. Similarly, for propolis, the number of
studies describing the bioavailability is limited. There is great difficulty in determining the
absorption and exertion of biological effects through systemic circulation at the desired site
of action, which can be affected by numerous factors, such as the food matrix, interactions
with other compounds, chemical structure, and concentration [44]. Further in vivo studies
are needed to establish the pharmacokinetics of the two substances in order to achieve the
desired concentration at the target site.
The dose of MAEC used in this study was safe for oral administration, as there was
no difference with the placebo group in terms of the reported incidences, and results from
physical examinations and pathologic tests were within the normal range. The lethal dose
for rodents was 1000 mg/kg, and the effective dose for anti-tumor activity was found
to be between 100 and 200 mg/kg [45], which was much higher than the dose in this
study (2.8 mg/kg of MAEC). No adverse events have been reported using mangosteen and
propolis extracts separately in previous clinical studies [15,20]. In general, these substances
are considered very safe and without side effects, and this study showed that safety was
maintained when the two substances were used together.
OHIP-14 questionnaire utilized in this study revealed that the patients experienced
improvement in oral health by taking the MAEC capsules daily. OHIP-14 is an abbreviated
version of the OHIP-49, a 49-item questionnaire that measures people’s perceptions of
the impact of oral conditions on their well-being and has been shown to produce good
reliability, validity, and precision [28]. Among the seven domains of the questionnaire,
significant outcomes were achieved in the most relevant domains—functional limitation
and physical disability, in which the patients experienced improved sense of taste and felt
the diet was more satisfactory. It is common knowledge that better dietary function can
lead to better overall health and quality of life. In a previous clinical trial, the test group,
after taking xanthone-rich mangosteen product, showed significantly enhanced immune
responses and improved subject’s self-appraisal on overall health status compared to the
placebo [46].
In fact, the blood tests at the end of the study showed that the test group exhibited sig-
nificantly increased levels of RBC, Hb, and Hct within the limits of normality compared to
the placebo group. A recent clinical study involving nearly 1000 subjects revealed that the
increases in the levels of Hct, Hb, and RBC within the normal ranges were beneficial for the
maintenance of vascular function and structure, which may decrease the risk of cardiovas-
cular disease [47]. Propolis has been extensively studied for its cardiovascular therapeutic
potential [48]. A randomized clinical trial on healthy subjects showed that orally adminis-
tered propolis supplement resulted in a significant decrease in BP after two months [49].
Another double-blinded placebo controlled study demonstrated that oral administration of
propolis solution decreased BP in hypertensive patients over 90 days [50]. Positive antioxi-
dant and anti-inflammatory properties of propolis are attributed to caffeic acid phenethyl
ester and the total flavonoid content, the latter being the main ingredient of the MAEC
in this study. In a study using rodents, animals were subjected to isoproterenol-induced
myocardial infarction. Treatment with α-mangostin resulted in alleviation of oxidative
changes and lipid peroxidation owing to the antioxidant property of α-mangostin [51]. The
results from the present study together with the evidence in the literature suggest that the
MAEC may have some added benefits for the cardiovascular system.
Various supplementary substances from natural extracts had been reported previously
for reduction of gingival inflammation. For instance, a combination of vitamin C, vitamin
E, lysozyme, and carbazochrome showed efficacy for reduction of GI [52]. Green tea extract
has been also considered due to the biological activity of its polyphenols namely catechins.
This substance was shown to have a therapeutic effect on the damaged periodontal tissue
when orally administered [53].
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5. Conclusions
In summary, in consideration of the significant reduction in modified GI, the MAEC
used in this study might exhibit anti-inflammatory potential. The immunological parame-
ters were inconclusive to determine the complex interactions between the MAEC, innate
immune system, and the cascade of MMP/cytokine reactions. This data should be inter-
preted with caution and remain open for discussion in future research. The dose of MAEC
was safe for oral administration. Enhanced parameters from blood tests along with PROM
can place MAEC in the positive light as a dietary supplement.
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